Literature DB >> 9836088

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.

A Kornbluth1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836088     DOI： 10.1002/ibd.3780040415

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  27 in total

Review 1.  Antibodies against G-protein coupled receptors: novel uses in screening and drug development.

Authors:  Achla Gupta; Andrea S Heimann; Ivone Gomes; Lakshmi A Devi
Journal:  Comb Chem High Throughput Screen       Date:  2008-07       Impact factor: 1.339

2.  Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease.

Authors:  V Galati; E Grilli; E Busi Rizzi; C Prantera; N Petrosillo
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

3.  A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.

Authors:  Mateus Dalcin Luchese; Mariana Lopes Dos Santos; Angelica Garbuio; Roselaine Campos Targino; Carla Ploeger Mansueli; Lilian Rumi Tsuruta; Wagner Quintilio; Ana Maria Moro
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

Review 4.  The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.

Authors:  M Anthony Sofia; David T Rubin
Journal:  Dig Dis Sci       Date:  2017-04       Impact factor: 3.199

5.  The Role of Biosimilars in Inflammatory Bowel Disease.

Authors:  Sudarshan Paramsothy; Noa Krugliak Cleveland; Nada Zmeter; David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-12

Review 6.  Golimumab and malignancies: true or false association?

Authors:  Ines Zidi; Aicha Bouaziz; Wissem Mnif; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

Review 7.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

8.  Trends in the Surgical Management of Crohn's Disease.

Authors:  Cristina B Geltzeiler; Kyle D Hart; Kim C Lu; Karen E Deveney; Daniel O Herzig; Vassiliki L Tsikitis
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

9.  Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.

Authors:  Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

10.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Authors:  T Ljung; P Karlén; D Schmidt; P M Hellström; A Lapidus; I Janczewska; U Sjöqvist; R Löfberg
Journal:  Gut       Date:  2004-06       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.